secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2026-06-12T20:59:44+00:00
Accession:  0001104659-26-073559
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma shareholders elect all director nominees, ratify auditor, approve say-on-pay
--------------------------------------------------------------------------------

- All six director nominees elected with >98% of votes cast in favor, including Laurie Smaldone Alsup and Susannah Gray.
- Ernst & Young LLP ratified as independent auditor for FY 2026 with 46.5M for, 572.9K against.
- Non-binding advisory resolution on named executive officer compensation approved with 42.6M for, 221.2K against.
- Proxies represented 91.4% of outstanding shares (47.06M), quorum established.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926073559/0001104659-26-073559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926073559/tm2617876d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-073559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer